Staff ReportsDr. Marty Makary is gone as commissioner of the Food and Drug Administration, and Kyle Diamantas — the agency’s deputy for human foods — will step in as acting leader. This sudden change is the latest chapter in a short, rocky run that saw the FDA mired in fights over the abortion pill, flavored vapes, and frayed relations with drugmakers and career staff. For conservatives, it is a moment to demand real accountability and a clearer, safer direction for the agency.
Makary out; Kyle Diamantas named acting FDA leader
The resignation came after months of mounting tension inside the agency and complaints from allies and critics alike. President Donald Trump confirmed the leadership change and praised Makary personally while naming Kyle Diamantas to serve in an acting capacity. Health and Human Services Secretary Robert F. Kennedy Jr. played a central role in the decision, signaling this was driven from the top of the administration. The switch is immediate and puts the food program chief in charge of the entire FDA for now.
Why he left: mifepristone fights, vapes, and industry blowback
The reporting points to several clashes that built up into a breaking point. Conservatives were furious over Makary’s handling of mifepristone, accusing him of slow‑walking reviews and putting pro‑abortion allies into key roles. At the same time, he tangled with the White House over flavored e‑cigarette authorizations after raising public health concerns. Biopharma companies also complained about inconsistent regulatory reviews, and career staff departures left morale in tatters. Put simply: he managed to upset almost everyone, from pro‑life activists to industry executives and career scientists.
Why conservatives cheered — and what to watch next
Republican critics hailed the resignation as a chance to reset the FDA toward common‑sense policy and better oversight. That reaction is expected. Conservatives rightly want an agency that defends life, protects kids from nicotine addiction, and restores fairness in drug approvals. But applause alone won’t fix an agency that has seen high turnover and bruised relationships with its own experts. The question now is whether the administration will appoint a permanent commissioner who can rebuild trust, enforce consistent standards, and stop letting political theater drive scientific decisions.
What needs fixing at the FDA
Time for competence over chaos
This is an opportunity to put someone in charge who values steady leadership, respects career staff, and follows sound science — not headlines. The acting appointment of Kyle Diamantas buys time, but conservatives should press for a permanent nominee who will protect children, defend legitimate life concerns about mifepristone policy, and hold the vaping industry accountable while helping adult smokers quit. The FDA needs a reset: clearer priorities, restored morale, and predictable rules so businesses and patients know what to expect. If Washington wants real reform, it should treat this moment as the start of a serious course correction — not just another personnel shuffle.
